A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer

Part of paid clinical trials in East Hanover, New Jersey.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07677254
Status
Recruiting
Apply to this trial

Conditions

  • Prostatic Neoplasms, Castration-Resistant

Eligibility Criteria

Sex
MALE
Age
18 Years - 115 Years
Healthy Volunteers
Not accepted

Study Details

The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Key Dates

First listed
Jun 30, 2026
Start date
Jun 30, 2026
Status verified
Jul 2026
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
17,111 participants (estimated)

Arms

  • Arm: mCRPC Cohort
    Adult male patients with a recent diagnosis of mCRPC in PRECISION.

Primary Outcome Measure

Number of Patients by Prior Therapies [ Time Frame: Baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NovartisEast HanoverNew Jersey07936-

Find similar trials in East Hanover, NJ

By research site
Novartis· East Hanover, NJ

Related Studies